Business
COG to present at Mello 2026
Cambridge Cognition Holdings plc will present at the Mello 2026 investor event, following strong financial results for FY 2025 which showed a 73% increase in new sales orders to £12.8 million and a 21% rise in the order book to £16.5 million. The company has also launched its professional and consumer healthcare business with new agreements and announced a 45,000 participant Brain Health Study with OURA, highlighting its expansion into scalable digital cognitive assessments for broader market applications. Disclaimer*
About this update from Cambridge Cognition Holdings Plc
Cambridge Cognition Holdings plc ("Cambridge Cognition", the "Company" or the "Group") COG to present at Mello 2026 Cambridge, UK, 1 June 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces that the Company will be presenting at the Mello 2026 investor event. Rob Baker, CEO, will present on Wednesday, 3 June 2026, at The Clayton Hotel & Conference Centre, Chiswick High Road, London, W4 5RY. Rob will be joined by other members of the senior leadership team to take investors questions during the day. The presentation follows a series of recent positive news events including: · FY 2025 financial results showing a 73% increase in new sales orders to £12.8m and a 21% increase in the order book £16.5m; · The launch of the professional healthcare and consumer health business with agreements with a major European healthcare provider, and an agreement with venture backed Ivory for the Indian market; and · The announcement of a 45,000 participant IRB-approved Brain Health Study with the world's leading smart ring maker OURA. Rob's presentation titled "Making Brain Health Measurable At Scale" addresses how Cambridge Cognition has built on 30 years of neuroscience and technology development, with its digital touch-screen and voice-based cognitive assessments. These have been used for decades supporting academic researchers and clinical drug development and are now being taken into the professional healthcare and consumer health & wellness market. These markets require highly scalable, reliable, consistent and accurate information delivered without administrator bias in near real time to users. For further information please visit the event website at www.melloevents.com ENQUIRIES Cambridge Cognition Holdings plc Rob Baker, Chief Executive Officer Ronald Openshaw, Chief Financial Officer Tel: 01223 810700 [email protected] Cavendish Capital Markets Limited (NOMAD and Joint Broker) Geoff Nash / Elysia Bough / Joe Smith Harriet Ward Nigel Birks Tel: 020 7220 0500 Corporate Finance Corporate Broking LS Specialist Sales Singer Capital Markets Limited (Joint Broker) A...
View stock analysis, news, and events for Cambridge Cognition Holdings Plc